Humanigen teams up with Kite to treat a type of lymphoma cancer
Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the California-based biotech has forged a clinical collaboration with Gilead Sciences Inc's (NASDAQ:GILD) subsidiary Kite, to study its therapy lenzilumab, with Kite's drug called Yescarta in patients suffering with certain forms of lymphoma cancer.
Durrant says he expects this Phase 1/2 study to begin by the end of 2019.
Quick facts: Humanigen Inc
Market Cap: $92.48 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Humanigen Inc named herein, including the promotion by the Company of Humanigen Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE